Accounting for inflation within NICE cost-effectiveness thresholds
Why are some drugs that may be demonstrated as cost-effective not being recommended for reimbursement? PRECISIONadvisors Richard Macaulay and his co-author have published this influential study, uncovering that the NICE ICER thresholds have declined by 42.9% in real terms since 2004 (without accounting for inflation).
Upcoming Webinar: Methodological Borrowing versus Conceptual Blending: Reengineering Health Economics Processes with Modeling and Simulations
Join us on 7/28 @ 10:30 AM EST | 7:30 AM PDT for “Methodological Borrowing versus Conceptual Blending: Reengineering Health Economics Processes with Modeling and Simulations,” Featuring PRECISIONheor’s Ross Maclean and Anuj Mubayi.
On-Demand Webinar: Continuing the Conversation-The Future of Reimbursement for Cell and Gene Therapies
Expanding upon his presentation at the recent World EPA Congress, moderator Richard Macaulay and Precision Value & Health have assembled a unique panel of payers from UK, Germany, and Italy, plus experts within Precision to address how innovative reimbursement strategies for cell and gene therapies (C>s) will evolve.
Upcoming Conference: Digital Pharma Innovation Week
Attending Digital Pharma Innovation Week? Don’t miss PRECISIONxtract’s Marty Samples and Jon Bambalas’ presentation “Get Creative: How to Modernize Your Brand’s Pull Through Approach” June 15 at 1:35 PM EDT. Also stop by our virtual booth to connect with one of our experts.
Conference Video: Virtual ISPOR 2021
Congratulations to Richard Macaulay on his well-attended presentation “The New SMC-Ultra-Orphan Pathway: HTA Best Practice for Very Rare Diseases?” at Virtual ISPOR 2021. Did you miss Richard’s presentation?
The Importance of Qualitative Research in Enhancing Understanding of Treatment Decisions, Outcomes, and Value Assessment
Despite the strengths and historical dominance of quantitative research in the health care domain, the importance of rigorous qualitative research as both a complement to, and a mechanism for, augmenting quantitative methods is increasingly being recognized and used across health-related disciplines.
Understanding the Impact of COVID-19 on Schizophrenia Population Health Management: A Mixed-Methods Study of Population Health Decision Makers
In “Understanding the Impact of COVID-19 on Schizophrenia Population Health Management: A Mixed-Methods Study of Population Health Decision Makers”, PRECISIONheor authors Marlon Graf, Meaghan Roach, Priti Pednekar, and Jacki Chou sought to understand PHDMs’ perceptions of challenges, policies, and programs related to schizophrenia population health management, both generally and in the context of the COVID-19 pandemic.
Are YOU ready to make the most of China’s evolving pharmaceutical reimbursement landscape?
China, the second largest pharmaceutical market in the world (valued at more than $150 billion), is experiencing a paradigm shift characterized by a booming economy, a growing middle class, and an increasingly aged population with rising disease rates. By reviewing recent changes to the Chinese pricing and market access landscape, PRECISIONadvisors’ Andrea Ong and Laura Montani discuss how manufacturers can capitalise on this booming market.
(more…)
David Carr: Readout and Analysis of Two World Orphan Drug Congress 2021 panels
PRECISIONadvisor’s Director David Carr recently attended World Orphan Drug Conference 2021, and found two panels particularly insightful: “Outlook on European market access strategies for rare diseases” and “Pricing & reimbursement for rare diseases in the United States.” In case you couldn’t attend, David noted the key takeaways of each presentation.
(more…)
Epidemics Within the Pandemic: Shifting Priorities and Opportunities for Addressing Opioid and Mental Health Crises During Covid-19
A survey conducted by PRECISIONvalue of population health priorities among health systems and health plans since the onset of Covid-19 suggests that while mental health conditions have risen in priority, opioid use disorders have become alarmingly deprioritized. Precision’s Maureen Hennessey shares the survey data and offer observations and suggestions for opportunities for plans, delivery systems, and pharmaceutical manufacturers to address the mental health and substance use epidemics occurring within the COVID pandemic.
